MAP2K7 and neoplasm: CAA (HRAS-Q61R) cells were also highly sensitive to the MEK inhibitor cobimetinib (GDC-0973), though it has been reported less effective against mutant-RAS than mutant-BRAF-driven tumor models14, as well as the ERK inhibitor SCH772984, reported effective against RAS-driven cancer models16 (Fig. 2c).